BMO Maintains Buy Rating on Amgen with Target Price at $450

BMO Capital analyst Evan Seigerman has maintained his buy rating for Amgen (AMGN.US) and its target price of $450. According to TipRanks, which provides analysis data from financial analysts, Seigerman's success rate over the past year is 59.2%, with a total average return of 10.7%. This means that out of all his ratings, 59.2% have been successful in terms of generating positive returns for TipRanks' virtual portfolio.

TipRanks calculates its analysts' success rates and average returns based on their preliminary ratings and adjustments made throughout the year. The data is intended for informational purposes only and should not be considered an investment recommendation. Seigerman's 5-star rating indicates his strong past performance, with more stars representing better results.